Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants-Reference-Cited by-同舟云学术

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

Published:2005-02 Issue:2 Volume:128 Page:270-279
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Debiec-Rychter Maria,Cools Jan,Dumez Herlinde,Sciot Raf,Stul Michel,Mentens Nicole,Vranckx Hilde,Wasag Bartosz,Prenen Hans,Roesel Johannes,Hagemeijer Anne,Van Oosterom Allan,Marynen Peter

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference28 articles.

1. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors;Hirota;Science,1998

2. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors;Rubin;Cancer Res,2001

3. PDGFRA activating mutations in gastrointestinal stromal tumors;Heinrich;Science,2003

4. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal tumors;Van Oosterom;Lancet,2001

5. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors;Demetri;N Engl J Med,2002

Cited by 438 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor;Oncogene;2024-05-17

2. Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling;Molecular Carcinogenesis;2024-04-17

3. Multistage in silico approach to identify novel quinoline derivatives as potential c-kit kinase inhibitors;Journal of Biomolecular Structure and Dynamics;2024-01-29

4. TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors;British Journal of Cancer;2024-01-05

5. Gastrointestinal Malignancy: Genetic Implications to Clinical Applications;Cancer Treatment and Research;2024